Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Inhibition of FAK kinase activity preferentially targets cancer stem cells.

Kolev VN, Tam WF, Wright QG, McDermott SP, Vidal CM, Shapiro IM, Xu Q, Wicha MS, Pachter JA, Weaver DT.

Oncotarget. 2017 Jun 16;8(31):51733-51747. doi: 10.18632/oncotarget.18517. eCollection 2017 Aug 1.

2.

PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.

Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J, Weaver DT, Padval MV, Pachter JA, Xu Q.

Cancer Res. 2015 Jan 15;75(2):446-55. doi: 10.1158/0008-5472.CAN-14-1223. Epub 2014 Nov 28.

3.

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.

Lobera M, Madauss KP, Pohlhaus DT, Wright QG, Trocha M, Schmidt DR, Baloglu E, Trump RP, Head MS, Hofmann GA, Murray-Thompson M, Schwartz B, Chakravorty S, Wu Z, Mander PK, Kruidenier L, Reid RA, Burkhart W, Turunen BJ, Rong JX, Wagner C, Moyer MB, Wells C, Hong X, Moore JT, Williams JD, Soler D, Ghosh S, Nolan MA.

Nat Chem Biol. 2013 May;9(5):319-25. doi: 10.1038/nchembio.1223. Epub 2013 Mar 24.

PMID:
23524983

Supplemental Content

Loading ...
Support Center